Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 18/20 | 0.56 |
| ▸ | TNF | P01375 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401634 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2418982 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL29575414 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL9084958 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2453889 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2417963 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL14762587 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL2451299 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL616109 | 1.00 | TLR2 (0.56) | TLR2TNF | |
| SCHEMBL30869073 | 1.00 | TLR2 (0.56) | TLR2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242657-A1 | LIPOPEPTIDE BUILDING BLOCKS AND AGGREGATES | SHAPE BIOPHARMACEUTICALS AG (CH) | 2025-11-27 | — | — | WO | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2013036543-A2 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-1649861-B1 | Adjuvant compositions comprising a mineral salt and another immunostimulating compound | SANOFI PASTEUR LTD (CA) | 2009-05-13 | — | — | EP | disclosed |
| EP-1649861-A2 | Adjuvant compositions comprising a mineral salt and another immunostimulating compound | Sanofi Pasteur Limited (CA) | 2006-04-26 | — | — | EP | disclosed |
| EP-0765163-B8 | ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND | SANOFI PASTEUR LTD (CA) | 2006-03-08 | — | — | EP | disclosed |
| EP-0765163-B1 | ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND | AVENTIS PASTEUR (CA) | 2005-12-07 | — | — | EP | disclosed |
| US-6764682-B1 | IMMUNOMODULATOR MIXTURE OF ALUMINUM HYDROXIDE, ALUMINUM PHOSPHATE, CALCIUM PHOSPHATE, ZINC HYDROXIDE AND/OR CALCIUM HYDROXIDE WITH GLYCOSYLAMIDE | AVENTIS PASTEUR LIMITED (CA) | 2004-07-20 | — | — | US | disclosed |
| US-6290971-B1 | N-(2-DEOXY-2-L-LEUCYLAMINO-BETA-D-GLUCOPYRANOSYL)-N-OCTADECYL -DODECANAMIDE ACETATE. | AVENTIS PASTEUR LIMITED (CA) | 2001-09-18 | — | — | US | disclosed |
| EP-0765163-A2 | ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND | Cannaught Laboratories Limited (CA) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995034308-A2 | ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND | CONNAUGHT LABORATORIES LIMITED (CA) | 1995-12-21 | — | — | WO | disclosed |
| EP-0641776-A2 | Thioglycerol derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | TLR2 3203/4885TNF 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.